Vesanoid (tretinoin) / Roche - LARVOL DELTA

Restricted Anthracycline Strategy in Pediatric Acute Promyelocytic Leukemia - A Single Centre Experience. (PubMed, Indian J Hematol Blood Transfus) - "An ATO-ATRA (Arsenic trioxide-All trans retinoic acid) based treatment protocol was employed, but with a unique strategy that restricts anthracycline use to progressive leucocytosis, irrespective of risk stratification. While three were lost to follow-up thereafter, the remaining 9 (75%) completed consolidation and are in long-term molecular remission. Hydroxyurea as a cytoreductive agent in APML allows for restricting anthracycline use to progressive leucocytosis without compromising outcomes."

Journal • Acute Promyelocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pediatrics

FIRST RESULTS OF THE APOLLO TRIAL: A RANDOMIZED PHASE III STUDY TO COMPARE ATO COMBINED WITH ATRA VERSUS STANDARD AIDA REGIMEN FOR PATIENTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE PROMYELOCYTIC LEUKEMIA (EHA 2024) - "Background: Pioneered by the APL0406 trial (Lo-Coco et al., NEJM 2013), prior investigations have demonstrated the superiority of combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) over standard ATRA and chemotherapy (CHT) as front-line management of low/intermediate risk acute promyelocytic leukemia (APL)...Death in CR/CRi were observed in 0 and 3 pts in the ATRA-ATO and ATRA-CHT arm, respectively... First-line therapy with ATRA-ATO with two initial doses idarubicin results in superior EFS compared to conventional ATRA-CHT in patients with HR-APL. Further analysis of the APOLLO trial may support the implementation of this regimen as the new standard of care in patients with HR-APL"

Clinical • P3 data • Acute Promyelocytic Leukemia • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Septic Shock • Thrombosis

Analysis of Cytogenetics, Molecular Profiling, and Survival in 190 Children With Newly Diagnosed Acute Myeloid Leukemia: A Single-Center Experience (SOHO 2026) - "This group was treated only with the combination of arsenic trioxide plus all-trans retinoic acid (ATO+ATRA)...Sorafenib was also used in FLT-positive patients... The findings corroborate the established prognostic relevance of the identified cytogenetic abnormalities in pediatric AML. Treatment outcomes were additionally influenced by infectious complications, nutritional status, the adequacy of intensive supportive care, and limited access to bone marrow transplantation and targeted therapy. AF6: afadin, adherens junction formation factor (also known as AFDN), AML1: RUNX family transcription factor 1 (also known as RUNX1), ETO: RUNX1 partner transcriptional co-repressor 1 (also known as RUNX1T1), FLT3: fms related receptor tyrosine kinase 3, ITD: internal tandem duplication, KMT2A: lysine methyltransferase 2A, MLL: mixed lineage leukemia, MLLT10: MLLT10 histone lysine methyltransferase DOT1L cofactor, PML: PML nuclear body scaffold, RARA: retinoic acid receptor alpha."

Clinical • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • DOT1L • FLT3 • KMT2A • MLLT10 • NPM1 • PML • RARA • RUNX1 • RUNX1T1

Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. (PubMed, Cancer) - P2 | "The combination of ATO-ATRA and GO was curative in 94% of patients who had APL with a favorable safety profile (ClinicalTrials.gov identifier NCT01409161)."

Journal • P2 data • Acute Promyelocytic Leukemia • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Oncology

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. (PubMed, J Clin Oncol) - P3 | "The results of the APOLLO trial support the use of ATO and ATRA for the treatment of newly diagnosed patients with high-risk APL."

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology

Steroid-Associated Toxicities and Survival Outcomes in Acute Promyelocytic Leukemia Treated With ATO/ATRA With or Without Chemotherapy (SOHO 2026) - "Context: Use of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APML) is associated with differentiation syndrome, prompting the use of prophylactic steroids. The frequent occurrence of differentiation syndrome during APML treatment and the metabolic complications associated with steroid use highlight the need for careful clinical monitoring and improved supportive care."

Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Therapy Based on Attenuated Arsenic Trioxide Plus Low-Dose All-Trans-Retinoic Acid in Acute Promyelocytic Leukemia. Is Less More? (ASH 2024) - P1/2 | "If high-risk (WBC >10 x109/L at presentation) a mitoxantrone 10 mg/m2/day was added on day 1...Differentiation syndrome (DS) prophylaxis with dexamethasone and hydroxyurea or anthracycline was used; supportive transfusion care as needed to reach goals...Despite ATO and ATRA ED remains the main problem in our context. This therapy was effective and safe, even for outpatient use after the late induction phase. This approach is promising, although further follow-up and validation studies are needed to confirm our results."

Acute Kidney Injury • Acute Promyelocytic Leukemia • CNS Disorders • Gastroenterology • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • PML

Efficacy of Topical Tretinoin and Topical Minoxidil Cotherapy in Androgenetic Alopecia: A Review. (PubMed, Skin Appendage Disord) - "Though current evidence does not support the first-line use of dual therapy, topical tretinoin may be considered as an adjunct in AGA, especially in patients without response to topical minoxidil. Any potential benefit, however, should be weighed against the potential for increased irritation."

Journal • Alopecia • Dermatology • Immunology

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Dwight Owen | Trial completion date: Dec 2026 ➔ Jul 2026 | Active, not recruiting ➔ Completed

Trial completion • Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • PD-L1

Acute promyelocytic leukemia with myelofibrosis and thrombocytosis: does the MPL gene mutation play a role? (ISTH 2026) - "Arsenic trioxide (ATO) was used to decrease white blood cell count...We increased the dose of ruxolitinib, clopidogrel plus aspirin was used...Now the patient is on ATO and ATRA maintenance together with ruxolitinib and anti-platelet therapy to keep his platelet count not more than 500×10 9 /L. Conclusions The MPL and NRAS mutations may be the underlying pathogenesis of the patient's thrombocytosis and myelofibrosis which was worthy of further study. DOI*10.1016/j.rpth.2026.106206"

Acute Promyelocytic Leukemia • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Myelofibrosis • Pneumonia • Respiratory Diseases • Thrombocytosis • IL2RA • ISG20 • NRAS • RARA

New Agents for Acne Treatment and Updates to Isotretinoin Guidelines. (PubMed, Pediatr Clin North Am) - "New topical treatments include tazarotene lotion, trifarotene, combined microencapsulated benzoyl peroxide and tretinoin, minocycline foam, topical dapsone, and clascoterone cream. More recent systemic options include subantimicrobial doxycycline, sarecycline, combined oral contraceptives, spironolactone, and isotretinoin-lidose."

Journal • Review • Acne Vulgaris

RARRES1 Is Highly Expressed in Thyroid Eye Disease Orbital Fibroblasts and Regulates IL-17 -Dependent MCP-1 Production (ENDO 2026) - "To support this hypothesis, we discovered that siRNA-mediated depletion of RARRES1 reduces IL-17/atRA-induced MCP-1 production. These studies support the concept that RA signaling promotes the inflammatory microenvironment in TED orbits and may be a target for future therapeutic interventions."

Endocrine Disorders • Grave’s Disease • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Optic Neuritis • Thyroid Eye Disease • CCL2 • CXCL8 • IL17A • IL6 • RARRES1

RARRES1 Is Highly Expressed in Thyroid Eye Disease Orbital Fibroblasts and Regulates IL-17 -Dependent MCP-1 Production (ENDO 2026) - "To support this hypothesis, we discovered that siRNA-mediated depletion of RARRES1 reduces IL-17/atRA-induced MCP-1 production. These studies support the concept that RA signaling promotes the inflammatory microenvironment in TED orbits and may be a target for future therapeutic interventions."

Endocrine Disorders • Grave’s Disease • Immunology • Inflammation • Ocular Inflammation • Ophthalmology • Optic Neuritis • Thyroid Eye Disease • CCL2 • CXCL8 • IL17A • IL6 • RARRES1

QUATRO-APL: A PIVOTAL OPEN-LABEL PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF QTX-2101 IN COMBINATION WITH ALL-TRANS RETINOIC ACID IN NEWLY DIAGNOSED, LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (EHA 2026) - "Background Intravenous (IV) arsenic trioxide (ATO) combined with all ‑ trans retinoic acid (ATRA) has transformed outcomes in a ll risk acute promyelocytic leukemia, leading to >90% molecular complete remission ( mCR ) rates and favorable l ong ‑ term survival...Aims Th is is a randomized, open ‑ label, multicenter Phase 3 study evaluating the efficacy and safety of oral QTX ‑ 2101 plus ATRA compared with IV ATO plus ATRA in adults with newly diagnosed l ow- ri sk acute promyelocytic leukemia (LR-APL)...Based on prior clinical experience, the lower C max associated with oral QTX ‑ 2101 may support improved tolerability versus IV ATO; effects on QTc and other safety parameters will be assessed in this study. With comparable systemic exposure, QTX ‑ 2101 is intended to m aintain the established efficacy of IV ATO while reducing treatment burden , enabling a fully oral approach for patients with LR ‑ APL with the potential to e stablish a new frontline standard of care."

Clinical • Combination therapy • P3 data • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • PML

OUTCOMES OF ACUTE PROMYELOCYTIC LEUKEMIA IN PATIENTS AGED ≥70 YEARS: A MULTICENTER REAL-WORLD ANALYSIS OF FIRST-LINE ATO-BASED THERAPY (EHA 2026) - "Arsenic trioxide (ATO)-based regimens are better tolerated, but patients aged ≥70 years have limited data due to the rarity of APL at this age and their exclusion from the ATO clinical trials. Figure 1. Overall survival of patients with APL treated with first-line ATO plus ATRA by patient age group."

Clinical • Real-world • Real-world evidence • Acute Promyelocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Nephrology • Pulmonary Arterial Hypertension • Renal Disease • Septic Shock • Thrombosis

POPULATION-BASED STUDY OF ACUTE PROMYELOCYTIC LEUKEMIA IN GERMANY: INCIDENCE AND SURVIVAL OUTCOMES (EHA 2026) - "The current standard of care combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has transformed APL into a highly curable disease in clinical trials. Modern ATO/ATRA therapy translates into favorable real-world survival, but outcomes remain worse than in trials, largely due to early deaths and poor results in the elderly. Strengthening rapid diagnostic pathways, early supportive care, and collaboration between specialized and community centers may further reduce early mortality and improve outcomes in this curable leukemia."

Clinical • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Thrombosis

ATO/ATRA-BASED REGIMEN OUTCOMES IN APML: STEROID USAGE IS A MAJOR CONCERN IN LMICS (MASCC-ISOO 2026) - "Relapses occurred in 6.36% (medullary: 57.1%, CNS: 14.2%, both: 28.5%). Conclusions Steroid-associated risks in APML patients poses significant challenges in LMICs and highlights the need for careful clinical monitoring and improved supportive care."

Acute Promyelocytic Leukemia • Diabetes • Hematological Disorders • Infectious Disease

Iron Complexes as Catalysts for Electrochemical Atom Transfer Radical Addition. (PubMed, Inorg Chem) - "A family of Fe-TPMA complexes comprising mononuclear [FeII(TPMA)(NCMe)2]2+ and [FeIII(TPMA)Cl2]+ as well as μ-oxido di-Fe complexes [(L(TPMA)FeIII)2O]n+ (L = H2O (n = 4); Cl-, Br- (n = 2)) were studied, which were structurally characterized and electrochemically analyzed in acetonitrile. Yields of ATRA product were dependent on the coligands present and in contrast to their highly reactive Cu-TPMA complexes, radical activation appears to be slower but advantageously this leads to fewer side products."

Journal

The effect of topical tretinoin use on topical minoxidil efficacy in androgenetic alopecia: A clinical review (SID 2026) - "Although mechanistic evidence for combined minoxidil/tretinoin suggests increased efficacy, clinical data are heterogeneous and limited. Nevertheless, it may benefit selected patients (particularly suspected non-responders)."

Clinical • Review • Alopecia • Immunology

Social media claims and tolerability of topical tretinoin plus topical minoxidil for androgenetic alopecia (SID 2026) - "Mentions of tolerability and sentiment were similar. Social media portrays combination therapy as effective, but any potential benefit should be balanced against side effect concerns, which may limit adherence."

Alopecia • Immunology • Pruritus

Evaluating Outcomes in Acute Promyelocytic Leukemia Patients Treated with All-Trans-Retinoic Acid and Arsenic Trioxide. (PubMed, Indian J Hematol Blood Transfus) - "Acute promyelocytic leukemia (APML) is characterized by promyelocytic leukemia retinoic acid receptor alpha (PML-RARA) fusion gene resulting from at (15;17) translocation. While, TLC significantly decreased from baseline in high risk cases to last follow-up (24 × 109/L vs. 9 × 109/L; P = 0.016). Patients with APML can be successfully treated with a combination of ATO and ATRA."

Journal • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • ANPEP • CD33 • KIT • PML • RARA

QUATRO-APL: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov) - P3 | N=150 | Recruiting | Sponsor: Quetzal Therapeutics

New P3 trial • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • PML

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia (clinicaltrials.gov) - P3 | N=158 | Active, not recruiting | Sponsor: Children's Oncology Group | Trial completion date: Sep 2025 ➔ Jun 2029

Trial completion date • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • PML • RARA

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: Dwight Owen | Trial completion date: Jan 2026 ➔ Dec 2026

Trial completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • PD-L1

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: Dwight Owen | Trial primary completion date: Jan 2026 ➔ Sep 2025

Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • PD-L1